<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01802346</url>
  </required_header>
  <id_info>
    <org_study_id>0S-10-3</org_study_id>
    <secondary_id>NCI-2013-00414</secondary_id>
    <nct_id>NCT01802346</nct_id>
  </id_info>
  <brief_title>Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer</brief_title>
  <official_title>A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well a controlled low calorie diet works in
      reducing side effects and increasing response to chemotherapy in patients with breast or
      prostate cancer. Drugs used in chemotherapy work in different ways to stop the growth of
      cancer cells, either by killing the cells or by stopping them from dividing. Eating a special
      diet with low calories may reduce the side effects of chemotherapy and improve the response
      to treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To obtain preliminary estimates of the impact of a restricted diet on toxicity and
      efficacy of chemotherapy for breast and prostate cancer.

      II. To evaluate the compliance with a controlled diet intervention.

      III. To investigate changes in plasma insulin, glucose, insulin-like growth factor 1 (IGF1)
      and IGF binding protein (IGFBP) levels in subjects who consume a restricted diet compared to
      controls.

      OUTLINE:

      Patients are randomized to 1 or 2 treatment arms.

      ARM I: Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during
      the 12 weeks of chemotherapy, and 24 hours after chemotherapy. Patients are provided with all
      meals and all food to be consumed and maintain a diary of the food consumed and appropriate
      amounts. Patients meet with the study dietician within 3 weeks of enrollment and prior to, or
      on the day of, their first course of chemotherapy on study and at the start of each
      subsequent course.

      ARM II: Patients eat a normal diet and receive dietary advice which may include consultation
      with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2013</start_date>
  <completion_date type="Anticipated">January 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of chemotherapy-related toxicity</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Occurrence of Grade 2+ non-hematologic symptomatic toxicity (fatigue, nausea and vomiting, anorexia, neuropathy, mucositis, cystitis, stomatitis), evaluated according to Common Terminology Criteria for Adverse Events version 4.0. The two arms will be compared, in terms of the proportion of patients with the occurrence of one of these toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Measured using a summary statistic which includes Response Evaluation Criteria In Solid Tumors (RECIST) response, PSA response for men without measurable disease, pathologic complete response and clinical response for breast cancer patients. This rate will be compared between patients on the restricted diet and controls.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (low-calorie diet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy. Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (normal diet)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients eat a normal diet and receive dietary advice which may include consultation with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <description>Consume a low-calorie diet</description>
    <arm_group_label>Arm I (low-calorie diet)</arm_group_label>
    <other_name>Dietary Modification</other_name>
    <other_name>intervention, dietary</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nutritional support</intervention_name>
    <description>Receive dietary advice</description>
    <arm_group_label>Arm II (normal diet)</arm_group_label>
    <other_name>nutritional assessment</other_name>
    <other_name>nutritional care</other_name>
    <other_name>support, nutritional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (low-calorie diet)</arm_group_label>
    <arm_group_label>Arm II (normal diet)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast cancer for which chemotherapy with AC (doxorubicin
             plus cyclophosphamide) is being utilized in the neoadjuvant or adjuvant setting OR
             metastatic prostate adenocarcinoma for which Docetaxel will be administered

          -  Body mass index (BMI) &gt;= 18.5

          -  Subjects do not need to have measurable or evaluable disease; chemotherapy may be
             administered in the neoadjuvant, adjuvant, or metastatic setting

          -  Prior therapy:

               -  Breast cancer subjects may not have received prior chemotherapy, with the
                  exception of curative-intent chemotherapy for a separate malignancy more than 3
                  years ago

               -  Prostate cancer subjects may have received prior treatment with metronomic
                  cyclophosphamide as this is considered anti-angiogenic/immunomodulatory and not
                  cytotoxic

               -  Prostate cancer subjects may be receiving a 2nd course of docetaxel provided that
                  ** The first course resulted in a PSA response (&gt; 30% reduction in prostate
                  specific antigen [PSA] and/or improvement in radiographic findings or pain) and
                  the last dose was &gt;= 9 months ago

          -  Prior Radiotherapy is allowed, provided at least 2 weeks have elapsed from completion
             of radiotherapy to initiation of protocol treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2x upper limit
             of normal (ULN)

          -  Absolute neutrophil count (ANC) &gt; 1500

          -  Platelets (plts) &gt; 90,000

          -  Premenopausal women must have a negative pregnancy test and must agree to use barrier
             contraception throughout the study period

        Exclusion Criteria:

          -  Diabetes Mellitus

          -  Peripheral Neuropathy &gt;= grade 1

          -  Prior therapy with inhibitors of IGF-1

          -  Concurrent use of somatostatin

          -  Significant food allergies which would make the subject unable to consume the food
             provided (ex: shellfish, soy or egg allergy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David I Quinn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Kefauver, RN</last_name>
    <phone>323-865-0459</phone>
    <email>Cheryl.Kefauver@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartolo Santos, RN</last_name>
      <phone>323-409-4363</phone>
      <email>Bartolo.santos@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>David I. Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Oncology/Hematology‚ÄêNewport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Massopust</last_name>
      <email>Kristy.Massopust@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Diana Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>507-538-7623</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2013</study_first_submitted>
  <study_first_submitted_qc>February 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

